Co-Diagnostics Invited to Present at Stop TB Partnership Summit in Washington, D.C.
PRNewswire (Thu, 16-Apr 9:01 AM ET)
Co-Diagnostics to Showcase Co-Dx PCR Platform and CE-IVD Solutions at ESCMID 2026 in Munich, Germany
PRNewswire (Tue, 14-Apr 9:01 AM ET)
Co-Diagnostics Executives to Participate in European Trade Mission with Utah Governor and WTC Utah
PRNewswire (Thu, 9-Apr 9:00 AM ET)
PRNewswire (Thu, 2-Apr 9:02 AM ET)
Co-Diagnostics Reports Full Year 2025 Financial Results
PRNewswire (Tue, 31-Mar 4:01 PM ET)
PRNewswire (Wed, 25-Mar 8:00 AM ET)
CODX Expands South Asian Reach, Boosting Total Addressable Market to $13 Billion
Market Chameleon (Fri, 20-Mar 4:58 AM ET)
PRNewswire (Fri, 20-Mar 8:00 AM ET)
Co-Diagnostics Announces Fourth Quarter and Full Year 2025 Earnings Release Date and Webcast
PRNewswire (Tue, 17-Mar 9:01 AM ET)
Co-Diagnostics to Present at Medical Korea 2026
PRNewswire (Mon, 16-Mar 9:00 AM ET)
Co-Diagnostics Inc is a molecular diagnostics company. The company develops, manufactures, licenses, and commercializes reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA), including molecular tools for detection of infectious diseases. CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and others. The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.
Co-Diagnostics trades on the NASDAQ stock market under the symbol CODX.
As of April 17, 2026, CODX stock price climbed to $1.52 with 90,311 million shares trading.
CODX has a market cap of $3.18 million. This is considered a Sub-Micro Cap stock.
Last quarter Co-Diagnostics reported $263,922 in Revenue and -$16.65 earnings per share. This beat revenue expectation by $113,922 and missed earnings estimates by -$12.75.
CODX support price is $1.32 and resistance is $1.60 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CODX shares will trade within this expected range on the day.